Naproxen Zidovudine

Figure 6.17 The classification of 42 drugs in the (solubility-dose ratio, apparent permeability) plane of the QBCS. The intersection of the dashed lines drawn at the cutoff points form the region of the borderline drugs. Key 1 acetyl salicylic acid 2 atenolol 3 caffeine 4 carbamazepine 5 chlorpheniramine 6 chlorothiazide 7 cimetidine 8 clonidine 9 corticosterone 10 desipramine 11 dexamethasone 12 diazepam 13 digoxin 14 diltiazem 15 disopyramide 16 furosemide 17 gancidovir 18 glycine 19 grizeofulvin 20 hydrochlorothiazide 21 hydrocortisone 22 ibuprofen 23 indomethacine 24 ketoprofen 25 mannitol 26 metoprolol 27 naproxen 28 panadiplon 29 phenytoin 30 piroxicam 31 propanolol 32 quinidine 33 ranitidine 34 salicylic acid 35 saquinavir 36 scopolamine 37 sulfasalazine 38 sulpiride 39 testosterone 40 theophylline 41 verapamil HC1 42 zidovudine.

R-Oxazepam, naproxen, menthol, AZT (zidovudine), abacavir, acetaminophen, almokalant, carvedilol, chloramphenicol, epirubicin, I -hydroxy estragole, 5-hydroxy rofecoxib, lorazepam, menthol, 4-methylumbelliferone, 1-naphthol (low), 4-nitrophenol, octylgallate, propranolol, temazepam, maxipost... 

In vitro evidence suggests that chloramphenicol, indometacin and naproxen inhibit the glucuronidation of zidovudine. However, neither indometacin nor naproxen altered zidovudine pharmacokinetics in subsequent clinical studies. Dipyridamole did not alter zidovudine pharmacokinetics. 

Barry M, Howe J, Back D, Breckenridge A, Brettle R, Mitchell R, Beeching NJ, Nye FJ. The effects of indomethacin and naproxen on zidovudine pharmacokinetics. BrJ Clin Pharmacol (1993) 36, 82-5. 

Sahai J, Gallicano K, Garber G, Pakuts A, Hawley-Foss N, Huang L, McGilveray I, Cameron DW. Evaluation of the in vivo effect of naproxen on zidovudin harmacddnetics inpatients infected with human immunodeficiency virus. Clin Pharmacol 1ner 99 2) 52,464-70. 

---